Skip to main content
main-content

05.07.2018 | Gastrointestinal Oncology | Ausgabe 11/2018

Annals of Surgical Oncology 11/2018

Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study

Zeitschrift:
Annals of Surgical Oncology > Ausgabe 11/2018
Autoren:
MD, MSc Brice Malgras, MD, PhD Etienne Gayat, MD Olivier Aoun, MD, PhD Réa Lo Dico, MD, PhD Clarisse Eveno, MD Karine Pautrat, MD, MSc Jean-Baptiste Delhorme, MD, PhD Guillaume Passot, MD, PhD Frédéric Marchal, MD, PhD Olivia Sgarbura, MD, PhD Gwenael Ferron, MD, PhD Diane Goéré, MD, PhD Thierry Andre, MD, PhD Marc Pocard, on behalf of the RENAPE Network
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1245/​s10434-018-6631-2) contains supplementary material, which is available to authorized users.
Collaborators [RENAPE - French National Network of Peritoneal Surface Malignancies] are listed at the end of the manuscript (in the Acknowledgements).

Abstract

Background

The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improved the prognosis of selected patients with peritoneal mesothelioma (PM).

Objective

The objective of our study was to evaluate whether different HIPEC agents were associated with different outcomes in patients with PM.

Methods

From the RENAPE database, we selected all patients with histology-proven PM who underwent CRS + HIPEC from 1989 to 2014. Inclusion criteria were age ≤ 80 years, performance status ≤ 2, and no extraperitoneal metastases.

Results

Overall, 249 patients underwent CRS + HIPEC for PM. The HIPEC regimen included five chemotherapeutic agents (CAs), consisting of cisplatin, doxorubicin, mitomycin-C, oxaliplatin, and irinotecan. When considering all CAs (alone or in combination), there was no significant statistical difference in regard to postoperative overall survival (OS). However, OS was better when using two CAs (group 2 drugs) versus one CA (group 1 drug) (p = 0.03). The different CA regimens were equally distributed between the two groups. This association between OS and HIPEC agent, as well as a trend for better progression-free survival, were both observed in the two-drug group versus the one-drug group (p = 0.009) for patients undergoing complete cytoreductive surgery (CC-0) with an epithelioid subtype.

Conclusions

This large study seems to show improved OS when combined CAs, especially with platinum-based regimens, are used for HIPEC in patients with PM, but needs to be confirmed by a randomized controlled trial.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Bis zum 22.10. bestellen und 100 € sparen!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (DOCX 90 kb)
10434_2018_6631_MOESM1_ESM.docx
Supplementary material 1 (tiff 1143 kb)
10434_2018_6631_MOESM2_ESM.tiff
Supplementary material 1 (tiff 1143 kb)
10434_2018_6631_MOESM3_ESM.tiff
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2018

Annals of Surgical Oncology 11/2018Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

 

 

 
 

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise